STUDY RESULTS 

GET IN FRONT of
moderate-to-severe eczema

with proven relief

GET IN FRONT of
moderate-to-severe eczema with proven relief

If you're struggling with symptoms, you're not alone. Some people who took CIBINQO in our clinical trials saw results. Visibly clearer skin and fast itch relief is possible with CIBINQO.

Take a look at the proof from our clinical studies

Clearer skin could be a reality

More people saw

75%

skin improvement

with CIBINQO vs an inactive
pill in just 3 months

more people saw a 75% skin improvement with CIBINQO™: 42% with 100mg, 62% with 200mg & 11% with inactive pill. See risk info In a ctive pil l 3 X M O R E PEOP L E vs inactive pill CIBI N Q O 100 m g C I B I N Q O 200 m g 42 % 62 % 11 %

More people achieved

clear or almost
clear skin

with CIBINQO vs an inactive
pill in just 3 months

people achieved clear/almost clear skin with CIBINQO™: 26% with 100mg, 41% with 200mg & 8% with inactive pill. See risk inf 3 X M O R E PEOP L E vs inactive pill 26 % C I B I N Q O 100 m g Inactive pill CIBI N Q O 200 m g 41 % 8 %

Less itch, quick results

After just

2 WEEKS

over 5X more people

felt quick and effective
itch relief taking
 CIBINQO 100 mg vs an inactive pill

after 2 weeks over 5x more people felt quick & effective itch relief taking CIBINQO™ 100mg vs an inactive pill. See risk info C I BINQ O 10 0 m g CIBI N Q O 200 m g I n a ctive pil l 11 % 26 % 2 %

Even after 3 MONTHS, more people felt itch relief taking CIBINQO vs an inactive pill

See how CIBINQO was studied

CIBINQO was studied in clinical trials of people with moderate-to-severe eczema. Participants received either CIBINQO or an inactive pill (also known as a placebo). These participants and their doctors were not told which one they received. In one study, people took either CIBINQO with topical steroids or an inactive pill with topical steroids. People were able to use a moisturizer in all of the studies.

Some of the trials lasted 3-4 months and focused on understanding the effectiveness and safety of CIBINQO. Improvement in area and severity of eczema-affected skin, skin clearance, and itch reduction were monitored.

Some of the people were able to enter another longer-term study that focused on safety.

Skin improvement, skin clearance, and itch reduction were monitored before, during, and at the end of the trials. The goal was to help answer the following question: Are patients who take CIBINQO more likely to have their eczema improve compared to patients who do not take CIBINQO?

Who participated in the studies?

Number of people studied

More than 1,600 people

Gender

53% male
47% female

Severity of AD (atopic dermatitis)

64% had moderate AD
36% had severe AD

Age

The average age was

36 years old

92% of people studied were 

18 years old and older 

8% of people studied were 12 to 17 years old*

*CIBINQO is not approved for use in pediatric patients.

Pfizer would like to thank everyone who participated in the CIBINQO clinical trials.

Seeing is believing

View photos and results that some people with moderate-to-severe eczema experienced in clinical trials.

Connect with a
nearby doctor

Schedule an appointment with your doctor today. If you don’t have one yet, you can find one using this tool.

Ready to ask about CIBINQO? 

To get the most out of your appointment,
use these tips and the doctor discussion
guide to help you prepare.